Increased SPHK1 expression is associated with poor prognosis in bladder cancer

详细信息    查看全文

• 作者：Xiao-Dong Meng (1) (2)
  Zhan-Song Zhou (1)
  Jian-Hong Qiu (2)
  Wen-Hao Shen (1)
  Qu Wu (3)
  Jun Xiao (4)
  
• 关键词：SPHK1 ; Bladder cancer ; Prognosis
• 刊名：Tumor Biology
• 出版年：2014
• 出版时间：March 2014
• 年：2014
• 卷：35
• 期：3
• 页码：2075-2080
• 全文大小：4,006 KB
• 参考文献：1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-6. doi:10.3322/caac.20121 . CrossRef
  2. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239-9. doi:10.1016/S0140-6736(09)60491-8 . CrossRef
  3. Pryor WA. Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Environ Health Perspect. 1997;105:875-2.
  4. Franekova M, Halasova E, Bukovska E, Luptak J, Dobrota D. Gene polymorphisms in bladder cancer. Urol Oncol. 2008;26:1-. doi:10.1016/j.urolonc.2006.10.011 . CrossRef
  5. Maceyka M, Payne SG, Milstien S, Spiegel S. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim Biophys Acta. 2002;1585:193-01. CrossRef
  6. Liu H, Chakravarty D, Maceyka M, Milstien S, Spiegel S. Sphingosine kinases: a novel family of lipid kinases. Prog Nucleic Acid Res Mol Biol. 2002;71:493-11. CrossRef
  7. Olivera A, Spiegel S. Sphingosine kinase: a mediator of vital cellular functions. Prostaglandins Other Lipid Mediat. 2001;64:123-4. CrossRef
  8. Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S, et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem. 2000;275:19513-0. doi:10.1074/jbc.M002759200 . CrossRef
  9. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol. 2005;64:695-05. CrossRef
  10. Kohno M, Momoi M, Oo ML, Paik JH, Lee YM, Venkataraman K, et al. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol. 2006;26:7211-3. CrossRef
  11. Le Scolan E, Pchejetski D, Banno Y, Denis N, Mayeux P, Vainchenker W, et al. Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood. 2005;106:1808-6. doi:10.1182/blood-2004-12-4832 . CrossRef
  12. Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim TJ, Murate T, et al. High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Biochem Biophys Res Commun. 2006;342:1284-0. CrossRef
  13. Kawamori T, Osta W, Johnson KR, Pettus BJ, Bielawski J, Tanaka T, et al. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J. 2006;20:386-. doi:10.1096/fj.05-4331fje .
  14. Guan H, Liu L, Cai J, Liu J, Ye C, Li M, et al. Sphingosine kinase 1 is overexpressed and promotes proliferation in human thyroid cancer. Mol Endocrinol. 2011;25:1858-6. doi:10.1210/me.2011-1048 . CrossRef
  15. Pan J, Tao YF, Zhou Z, Cao BR, Wu SY, Zhang YL, et al. An novel role of sphingosine kinase-1 (SPHK1) in the invasion and metastasis of esophageal carcinoma. J Transl Med. 2011;9:157. doi:10.1186/1479-5876-9-157 . CrossRef
  16. Fuereder T, Hoeflmayer D, Jaeger-Lansky A, Rasin-Streden D, Strommer S, Fisker N, et al. Sphingosine kinase 1 is a relevant molecular target in gastric cancer. Anticancer Drugs. 2011;22:245-2. CrossRef
  17. Bao M, Chen Z, Xu Y, Zhao Y, Zha R, Huang S, et al. Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma. Liver Int. 2012;32:331-. doi:10.1111/j.1478-3231.2011.02666.x . CrossRef
  18. Kalari S, Moolky N, Pendyala S, Berdyshev EV, Rolle C, Kanteti R, et al. Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation. PLoS One. 2012;7:e45330. doi:10.1371/journal.pone.0045330 . CrossRef
  19. Du ZM, Hu CF, Shao Q, Huang MY, Kou CW, Zhu XF, et al. Upregulation of caveolin-1 and CD147 expression in nasopharyngeal carcinoma enhanced tumor cell migration and correlated with poor prognosis of the patients. Int J Cancer. 2009;125(8):1832-1. doi:10.1002/ijc.24531 . CrossRef
  20. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 2010;9:3. doi:10.1186/1476-4598-9-3 . CrossRef
  21. Kim YK, Kim WJ. Epigenetic markers as promising prognosticators for bladder cancer. Int J Urol. 2009;16:17-2. doi:10.1111/j.1442-2042.2008.02143.x . CrossRef
  22. Habuchi T, Marberger M, Droller MJ, Hemstreet 3rd GP, Grossman HB, Schalken JA, et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology. 2005;66:64-4. doi:10.1016/j.urology.2005.08.065 . CrossRef
  23. Dyrskj?t L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, et al. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res. 2007;13:3545-1. doi:10.1158/1078-0432.CCR-06-2940 . CrossRef
  24. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005;11:2625-6. doi:10.1158/1078-0432.CCR-04-1988 . CrossRef
  25. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005;23:3526-5. doi:10.1200/JCO.2005.00.695 . CrossRef
  26. Kim WJ, Kim SK, Jeong P, Yun SJ, Cho IC, Kim IY, et al. A four-gene signature predicts disease progression in muscle invasive bladder cancer. Mol Med. 2011;17:478-5. doi:10.2119/molmed.2010.00274 .
  27. Liu G, Zheng H, Zhang Z, Wu Z, Xiong H, Li J, et al. Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy. BMC Cancer. 2010;10:495. doi:10.1186/1471-2407-10-495 . CrossRef
  28. Facchinetti MM, Gandini NA, Fermento ME, Sterin-Speziale NB, Ji Y, Patel V, et al. The expression of sphingosine kinase-1 in head and neck carcinoma. Cells Tissues Organs. 2010;192:314-4. doi:10.1159/000318173 . CrossRef
  29. Li W, Yu CP, Xia JT, Zhang L, Weng GX, Zheng HQ, et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 2009;15:1393-. doi:10.1158/1078-0432.CCR-08-1158 . CrossRef
  30. Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J, et al. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res. 2008;14:6996-003. doi:10.1158/1078-0432.CCR-08-0754 . CrossRef
  31. Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D’Amato C, et al. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res. 2013;19:138-7. doi:10.1158/1078-0432.CCR-12-1050 . CrossRef
  
• 作者单位：Xiao-Dong Meng (1) (2)
  Zhan-Song Zhou (1)
  Jian-Hong Qiu (2)
  Wen-Hao Shen (1)
  Qu Wu (3)
  Jun Xiao (4)
  
  1. Department of Urology, Southwest Hospital, The Third Military Medical University, No. 30, Gaotanyanzheng Street, Shapingba District, Chongqing, 40038, China
  2. Department of Urology, The Bethune International Peace Hospital, No. 398, Zhongshan West Road, Shijiazhuang, 050082, China
  3. The Bethune International Peace Hospital, No. 398, Zhongshan West Road, Shijiazhuang, 050082, China
  4. Department of Anesthesiology, The Bethune International Peace Hospital, No. 398, Zhongshan West Road, Shijiazhuang, 050082, China
  
• ISSN：1423-0380

文摘

Upregulation of sphingosine kinase 1 (SPHK1) protein has been reported to be associated with a poor prognosis in a variety of malignant tumors. However, the role of SPHK1 in bladder cancer (BC) has not been thoroughly elucidated. The purpose of this study was to assess SPHK1 expression and to explore its contribution to BC. Real-time quantitative reverse transcriptase–polymerase chain reaction (qRT-PCR) was conducted to detect SPHK1 mRNA expression in 37 pairs of fresh-frozen BC tissues and corresponding noncancerous tissues. Results showed that SPHK1 mRNA expression level in BC tissues was significantly higher than that in corresponding noncancerous tissues. To investigate the association between SPHK1 protein expression and clinicopathological characteristics of BC, immunohistochemistry (IHC) was performed in 153 archived paraffin-embedded BC samples. Interestingly, high SPHK1 expression was significantly associated with histologic grade (P--.045) and tumor stage (P-lt;-.001) of patients with BC. The Kaplan–Meier survival curve showed that patients with high SPHK1 expression had significantly reduced overall 5-year survival rates (P-lt;-.001). Multivariate Cox regression analysis further suggested that the increased expression of SPHK1 was an independent poor prognostic factor for this disease. In conclusion, our data offer the convincing evidence for the first time that the increased expression of SPHK1 may be involved in the pathogenesis and progression of BC. SPHK1 might be a potential marker to predict the prognosis in BC.